GlycoMimetics Inc (GLYC)
0.32
-0.01
(-3.03%)
USD |
NASDAQ |
Nov 21, 16:00
0.32
0.00 (0.00%)
After-Hours: 04:35
GlycoMimetics PS Ratio
PS Ratio Chart
Historical PS Ratio Data
Date | Value |
---|---|
March 30, 2022 | 51.02 |
March 29, 2022 | 51.46 |
March 28, 2022 | 51.91 |
March 25, 2022 | 54.57 |
March 24, 2022 | 56.79 |
March 23, 2022 | 55.01 |
March 22, 2022 | 55.90 |
March 21, 2022 | 53.24 |
March 18, 2022 | 53.24 |
March 17, 2022 | 51.46 |
March 16, 2022 | 47.91 |
March 15, 2022 | 45.70 |
March 14, 2022 | 44.37 |
March 11, 2022 | 48.80 |
March 10, 2022 | 51.46 |
March 09, 2022 | 48.80 |
March 08, 2022 | 46.58 |
March 07, 2022 | 46.58 |
March 04, 2022 | 47.47 |
March 03, 2022 | 48.36 |
March 02, 2022 | 60.34 |
March 01, 2022 | 56.34 |
February 28, 2022 | 54.57 |
February 25, 2022 | 52.79 |
February 24, 2022 | 49.69 |
Date | Value |
---|---|
February 23, 2022 | 49.25 |
February 22, 2022 | 49.25 |
February 18, 2022 | 49.25 |
February 17, 2022 | 49.69 |
February 16, 2022 | 47.47 |
February 15, 2022 | 47.03 |
February 14, 2022 | 46.14 |
February 11, 2022 | 48.36 |
February 10, 2022 | 47.47 |
February 09, 2022 | 48.80 |
February 08, 2022 | 46.58 |
February 07, 2022 | 47.47 |
February 04, 2022 | 47.91 |
February 03, 2022 | 47.03 |
February 02, 2022 | 48.36 |
February 01, 2022 | 52.79 |
January 31, 2022 | 52.79 |
January 28, 2022 | 50.80 |
January 27, 2022 | 47.47 |
January 26, 2022 | 50.13 |
January 25, 2022 | 50.13 |
January 24, 2022 | 47.91 |
January 21, 2022 | 49.25 |
January 20, 2022 | 52.35 |
January 19, 2022 | 53.24 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
40.11
Minimum
Aug 19 2021
84.66
Maximum
Sep 30 2021
56.75
Average
51.59
Median
PS Ratio Benchmarks
Biomarin Pharmaceutical Inc | 4.526 |
Arbutus Biopharma Corp | 92.54 |
Revance Therapeutics Inc | 1.446 |
FibroGen Inc | 0.2139 |
Cidara Therapeutics Inc | 1.433 |
PS Ratio Related Metrics
Price to Book Value | 1.814 |
Price | 0.32 |
Earnings Yield | -193.8% |
Market Cap | 20.63M |